Huatai-Pinebridge Fund Management Co., Ltd - Hang Seng Innovative Drug ETF (SHA:520500)
China · Delayed Price · Currency is CNY 1.235
+0.052 (4.40%)
At close: Jun 12, 2026
-22.91% (1Y)
| Assets | n/a |
| Expense Ratio | 0.60% |
| PE Ratio | 29.26 |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | n/a |
| Payout Frequency | n/a |
| Payout Ratio | n/a |
| 1-Year Return | -22.91% |
| Volume | 1,378,260,000 |
| Open | 1.197 |
| Previous Close | 1.183 |
| Day's Range | 1.181 - 1.241 |
| 52-Week Low | 1.161 |
| 52-Week High | 2.142 |
| Beta | n/a |
| Holdings | 33 |
| Inception Date | Dec 16, 2024 |
About 520500
520500.SS was created on 2024-12-16 by Huatai. The fund's investment portfolio concentrates primarily on health care equity. Closely track the performance of the underlying index and seek to minimize tracking deviation and tracking error.
Asset Class Equity
Category Health Care
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 520500
Provider Huatai
Index Tracked Hang Seng Innovative Drug
Performance
520500 had a total return of -22.91% in the past year, including dividends. Since the fund's inception, the average annual return has been 14.96%.
Top 10 Holdings
72.16% of assets| Name | Symbol | Weight |
|---|---|---|
| Akeso, Inc. | 9926 | 10.38% |
| BeOne Medicines AG | 6160 | 9.84% |
| Sino Biopharmaceutical Limited | 1177 | 9.83% |
| Innovent Biologics, Inc. | 1801 | 8.93% |
| Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 6990 | 8.07% |
| CSPC Pharmaceutical Group Limited | 1093 | 7.49% |
| 3SBio Inc. | 1530 | 5.43% |
| Hansoh Pharmaceutical Group Company Limited | 3692 | 4.35% |
| Everest Medicines Limited | 1952 | 4.13% |
| Zai Lab Limited | 9688 | 3.73% |